B. Riley Lowers Earnings Estimates for Nektar Therapeutics

Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Stock analysts at B. Riley cut their Q1 2025 EPS estimates for shares of Nektar Therapeutics in a research note issued to investors on Monday, May 5th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will post earnings per share of ($0.21) for the quarter, down from their prior forecast of ($0.19). The consensus estimate for Nektar Therapeutics' current full-year earnings is ($0.72) per share. B. Riley also issued estimates for Nektar Therapeutics' FY2025 earnings at ($0.81) EPS, FY2026 earnings at ($0.77) EPS and FY2028 earnings at ($0.71) EPS.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.04). Nektar Therapeutics had a negative return on equity of 173.28% and a negative net margin of 180.70%. The business had revenue of $10.46 million during the quarter, compared to the consensus estimate of $15.61 million. During the same quarter in the previous year, the business posted ($0.18) earnings per share.

A number of other research firms have also recently commented on NKTR. Oppenheimer upgraded shares of Nektar Therapeutics from a "market perform" rating to an "outperform" rating and set a $6.00 target price on the stock in a research note on Friday, March 14th. William Blair restated a "market perform" rating on shares of Nektar Therapeutics in a research note on Monday. HC Wainwright reaffirmed a "buy" rating and issued a $6.50 price objective on shares of Nektar Therapeutics in a research note on Thursday, March 13th. StockNews.com started coverage on shares of Nektar Therapeutics in a research report on Wednesday, April 16th. They set a "hold" rating for the company. Finally, Jefferies Financial Group upgraded shares of Nektar Therapeutics from a "hold" rating to a "buy" rating and lifted their price target for the company from $1.00 to $2.00 in a report on Friday, April 11th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $4.50.

Nektar Therapeutics Stock Up 0.7%

NKTR traded up $0.00 during midday trading on Thursday, reaching $0.72. The company had a trading volume of 1,635,954 shares, compared to its average volume of 1,839,570. The business has a 50-day moving average of $0.71 and a two-hundred day moving average of $0.90. Nektar Therapeutics has a 1 year low of $0.43 and a 1 year high of $1.93. The company has a market cap of $133.92 million, a P/E ratio of -0.86 and a beta of 0.62.

Institutional Trading of Nektar Therapeutics

Institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC lifted its holdings in shares of Nektar Therapeutics by 50.0% in the 3rd quarter. Jane Street Group LLC now owns 91,470 shares of the biopharmaceutical company's stock worth $119,000 after acquiring an additional 30,481 shares during the last quarter. Barclays PLC lifted its stake in Nektar Therapeutics by 96.1% in the third quarter. Barclays PLC now owns 358,294 shares of the biopharmaceutical company's stock worth $466,000 after purchasing an additional 175,596 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Nektar Therapeutics by 197.3% during the third quarter. JPMorgan Chase & Co. now owns 913,300 shares of the biopharmaceutical company's stock valued at $1,187,000 after buying an additional 606,057 shares during the period. HB Wealth Management LLC raised its holdings in shares of Nektar Therapeutics by 44.0% in the fourth quarter. HB Wealth Management LLC now owns 64,100 shares of the biopharmaceutical company's stock worth $60,000 after buying an additional 19,600 shares during the period. Finally, SG Americas Securities LLC grew its position in Nektar Therapeutics by 12.2% in the 4th quarter. SG Americas Securities LLC now owns 107,318 shares of the biopharmaceutical company's stock valued at $100,000 after acquiring an additional 11,681 shares during the last quarter. 75.88% of the stock is currently owned by institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.